a decreasing trendp < 0.001
reported that throughout the entire study period, the bexarotene group exhibited increased cholesterol levels, whereas the placebo group showed a decreasing trend (F 2,317 = 33.7, p < 0.001).
reported that throughout the entire study period, the bexarotene group exhibited increased cholesterol levels, whereas the placebo group showed a decreasing trend (F 2,317 = 33.7, p < 0.001).